FreeGuest Editorial 30 Years after Chernobyl: Lessons Learned April 25, 2016Vol.42 No.16By Robert Peter Gale
Comparison with AstraZeneca Drug Hard to Ignore as ODAC Votes Down NSCLC Application from Clovis April 25, 2016Vol.42 No.16By Paul Goldberg
Stand Up To Cancer Debuts Catalyst Research Program With Merck, BMS and Genentech April 18, 2016Vol.42 No.15
Free FDA Inspects Hospitals for Morcellation Harm; Congressman Draws VP Biden’s Attention to Issue April 18, 2016Vol.42 No.15By Matthew Bin Han Ong
Letter To The Editor Former MD Anderson Provost Reflects on “Brief, Painful Episode” April 18, 2016Vol.42 No.15By Raymond N. DuBois
Conversation with The Cancer LetterFree Parker Mantra: Collaborate Like Hell April 18, 2016Vol.42 No.15By Matthew Bin Han Ong
Free Parker Bets $250 Million on Immunotherapy April 18, 2016Vol.42 No.15By Paul Goldberg and Matthew Bin Han Ong
